|
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia. TELINTRA® is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
 5th Annual OneMedForum Conference
January 11, 2012
3:00 pm Eastern Time (12 Noon Pacific Time)
Click here for the webcast.
2010 Annual Report
2011 Proxy Statement
January 04 , 2012
Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference
December 13 , 2011
Telik Announces the Results of Genetic Signature Studies of Myelodysplastic Syndrome Patients Likely to Respond to Telintra® (Ezatiostat Hydrochloride, TLK199) at the Annual Meeting of the American Society of Hematology
December 13 , 2011
Telik Announces Phase 1 Results of a Multicenter Study of Telintra® (Ezatiostat Hydrochloride, TLK199) in Combination with Revlimid® (Lenalidomide) in Patients with Myelodysplastic Syndrome
|
